Skip to main content
. Author manuscript; available in PMC: 2010 Jul 23.
Published in final edited form as: Vaccine. 2009 Jun 9;27(34):4672–4683. doi: 10.1016/j.vaccine.2009.05.059

Figure 1. MPR peptides from the ectodomain of gp41.

Figure 1

Peptide immunogens were designed containing the N terminal region (N-MPR) or C terminal region (C-MPR) of the MPR. The sequences were comprised of the nominal epitopes of monoclonal antibodies 2F5 and 4E10 (underlined), respectively, with additional flanking sequences previously reported to improve binding [5, 6]. The C terminus was amended with a two residue linker and a lysine for on-resin lipid conjugation. A peptide spanning both the N and C terminal sequences (NC-MPR) contained both the 2F5 and the 4E10 epitopes with helix-promoting constraints at the C terminus [31]. ‘B’ indicates aminoisobutyric acid. FP – Fusion peptide; NHR – N heptad repeat; CHR – C heptad repeat; MPR – Membrane proximal region; TM – Transmembrane domain.